


The burden of antimicrobial resistance (AMR) in Tunisia

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **1,000 lives** have been lost each year since 1990 in Tunisia due to AMR.
- In 2021, there were an estimated **1,070 UI (747-1,390)** deaths attributable to AMR and **4,270 UI (3,030-5,500)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **70+** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Staphylococcus aureus* resistant to methicillin, *Acinetobacter baumannii* resistant to carbapenems and *Streptococcus pneumoniae* resistant to carbapenems.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Tunisia, a 10% reduction means to decrease the number of deaths associated with AMR to **3,960**, but currently the trend for this country could reach up to **5,330 UI [3,710-7,500]** AMR-associated deaths in 2030.

AMR in Tunisia

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Tunisia between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Tunisia** in 2021, there were an estimated **1,070 UI (747-1,390)** deaths attributable to AMR and **4,270 UI (3,030-5,500)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Tunisia has the 56th lowest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

	Overall susceptible and resistant	Associated	Attributable
Burden rank	Staphylococcus aureus 1,390 UI (1,020-1,760) ↑	Staphylococcus aureus 831 UI (556-1,110) ↑	Streptococcus pneumoniae 207 UI (138-277) ↓
	Escherichia coli 883 UI (651-1,120) ↑	Streptococcus pneumoniae 714 UI (510-918) ↓	Acinetobacter baumannii 197 UI (151-244) ↑
	Streptococcus pneumoniae 880 UI (643-1,120) ↓	Escherichia coli 689 UI (491-887) ↑	Staphylococcus aureus 175 UI (106-245) ↑
	Pseudomonas aeruginosa 646 UI (470-821) ↑	Acinetobacter baumannii 487 UI (354-620) ↑	Escherichia coli 126 UI (81-170) ↑
	Klebsiella pneumoniae 597 UI (435-759) ↓	Klebsiella pneumoniae 431 UI (306-555) ↓	Klebsiella pneumoniae 120 UI (86-154) ↑
	Acinetobacter baumannii 493 UI (358-628) ↑	Pseudomonas aeruginosa 380 UI (263-496) ↑	Pseudomonas aeruginosa 99 UI (62-137) ↑
	Enterococcus faecalis 245 UI (178-312) ↑	Enterococcus faecium 124 UI (88-159) ↑	Enterococcus faecium 29 UI (20-38) ↑
	Mycobacterium tuberculosis 235 UI (124-347) ↓	Enterococcus faecalis 118 UI (81-155) ↑	Enterobacter spp. 28 UI (20-35) ↓
	Enterobacter spp. 211 UI (153-269) ↑	Proteus spp. 106 UI (70-141) ↑	Enterococcus faecalis 23 UI (12-34) ↑
	Group A Streptococcus 204 UI (142-266) ↑	Enterobacter spp. 105 UI (74-136) ↑	Proteus spp. 18 UI (11-25) ↑

Annualized rate of change (1990-2021): <-3% (blue), -1.5% to 0% (light blue), 0% to 1.5% (pink), 1.5% to 3% (red), 3% to 5% (dark red), >5.0% (orange)


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

	Associated	Attributable
Burden Rank	Staphylococcus aureus Macrolides 727 UI (495-959) ↑	Streptococcus pneumoniae Carbapenems 169 UI (108-231) ↑
	Escherichia coli Aminopenicillin 654 UI (431-878) ↑	Staphylococcus aureus Methicillin 110 UI (58-162) ↑
	Streptococcus pneumoniae Carbapenems 584 UI (395-773) ↑	Acinetobacter baumannii Carbapenems 107 UI (75-138) ↑
	Streptococcus pneumoniae Macrolides 559 UI (396-722) ↑	Acinetobacter baumannii Fluoroquinolones 56 UI (44-69) ↑
	Acinetobacter baumannii Carbapenems 476 UI (347-605) ↑	Pseudomonas aeruginosa Carbapenems 53 UI (29-78) ↑
	Acinetobacter baumannii Beta-Lactam/Lactamase Inhib. 472 UI (343-601) ↑	Klebsiella pneumoniae Carbapenems 35 UI (24-46) ↑
	Acinetobacter baumannii 3GC 467 UI (340-594) ↑	Staphylococcus aureus Macrolides 33 UI (19-46) ↑
	Acinetobacter baumannii Anti-pseudomonal 465 UI (338-591) ↑	Klebsiella pneumoniae Aminoglycosides 32 UI (20-44) ↑
	Acinetobacter baumannii 4GC 464 UI (337-591) ↑	Acinetobacter baumannii Aminoglycosides 30 UI (20-40) ↑
	Staphylococcus aureus Methicillin 463 UI (222-705) ↑	Escherichia coli Beta-Lactam/Lactamase Inhib. 26 UI (4-49) ↑

Annualized rate of change (1990-2021): <-3% (blue), -3% to -1.5% (light blue), -1.5% to 0% (light blue), 0% to 1.5% (pink), 1.5% to 3% (red), 3% to 5% (dark red), >5.0% (orange)

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) bloodstream infections (3,740 UI (2,760-4,710)), lower respiratory infection (excl. COVID) (3,030 UI (2,170-3,880)), peritoneal and intra-abdominal infections (702 UI (481-924)), infections of the skin and subcutaneous systems (462 UI (295-630)) and urinary tract infections and pyelonephritis (381 UI (259-504)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Tunisia, people aged under 5 experienced the largest number of deaths associated with AMR in 1990 but this changed by 2021 as the largest number of deaths occurred among the 70+. This indicates that prevention of infections among the under 5 has contributed to the reduction in the number of AMR associated deaths. In 2021, the number of deaths associated with AMR among the 70+ was 2,520 UI (1,820-3,230), whereas the mortality rate per 100,000 was 363 UI (262-463).

Data sources for Tunisia

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Tunisia by source type

Source type	Years	Sample size	Sample size units
Antibiotic use	2010-2021	269	Study-year datapoints
Microbial or laboratory data without outcome	2010-2021	33,131	Isolates
Microbial or laboratory data with outcome	2010-2021	13	Isolates
Literature studies	1990-2021	16,808	Cases/isolates/susceptibility tests
Single drug resistance profile data	2010-2021	315,765	Antibiotic susceptibility test

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care’s Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>